PMG 1015
Alternative Names: PMG-1015Latest Information Update: 13 Jun 2023
At a glance
- Originator Pulmongene
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 19 May 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In adults, In the elderly) in China (IV) (NCT05895565)
- 10 Aug 2022 Pulmongene completes a phase I trial in Idiopathic Pulmonary Fibrosis (In Volunteers) in Australia (Parenteral) (NCT05022771)
- 01 Sep 2021 Preclinical trials in Idiopathic pulmonary fibrosis in Hong Kong (Parenteral)